WATCH NOW
Lexeo Therapeutics Webinar | May 2025
On Thursday, May 15, 2025, Lexeo Therapeutics joined FARA for an informational webinar discussing updates on LX2006. Theresa Zesiewicz, MD, from the USF Ataxia Research Center, and Greg Aubert, MD, from Lexeo Therapeutics, shared updates on LX2006—Lexeo’s investigational gene therapy candidate for the treatment of Friedreich’s ataxia cardiomyopathy. The presentation included recent data from the SUNRISE-FA Phase 1/2 clinical trial, as well as information on the CLARITY-FA natural history study, which will soon begin enrolling participants in the U.S.
